A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Donanemab in Adults With Down Syndrome

The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
The main questions it aims to answer are: Does donanemab reduce amyloid in the brain? Is donanemab safe and well-tolerated in people with Down syndrome? Researchers will compare donanemab to a placebo (a look-alike substance that contains no drug) to see if donanemab works to reduce levels of amyloid in the brain.
Participants in the study will be 35-50 years old and will be in the study for 12 months. Participants will then stay in the study for an additional 12 months in an long-term extension where all participants will receive donanemab. Participants who had a reduction in amyloid (measured by amyloid brain scan) by the end of the first 12 months will receive placebo for the long-term extension, while participants who did not have an amyloid reduction will receive study donanemab for the long-term extension. Everyone (participants and study staff) will remain blinded to treatment for the duration of the study.
Participants will:
* Have intravenous (IV) infusions of donanemab (or placebo) every 4 weeks
* Visit the clinic once every other month for checkups and tests. These tests will include brain scans (magnetic resonance imaging [MRI] and positron emission tomography [PET] ), blood draws and memory tests.
* Have a study partner who who can provide information about the participant and can join participant for some of the study visits.

Start Date01 Aug 2026

Sponsor / Collaborator

University of Southern California

[+3]

NCT06996730

/ Not yet recruitingPhase 2/3IIT

A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease

The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18 months (76 weeks), with a minimum treatment period of 9 months. Amyloid PET scans will be conducted at screening, 9, and 18 months in Part 1. Participants who are at or below 11 CL at screening or reach complete amyloid plaque clearance as measured by florbetapir F18 PET (defined as ≤11 CL) at 9 months will initiate Part 2. Participants who are ≤11 CL at screening may delay their entry into Part 2 for up to 6 months at the discretion of the Investigator. All remaining participants will start Part 2 after completing 18 months (76 weeks) in Part 1 independent of amyloid results. Non-carriers will receive placebo in both Parts 1 and 2.
In Part 2, study participants who are mutation carriers will be randomized 1:1:1:1 in a full factorial design to receive either RG6289 + placebo-donanemab (RG6289 alone group), donanemab + placebo-RG6289 (donanemab alone group), the combination of RG6289 and donanemab (combination group), or placebo-RG6289 and placebo-donanemab (placebo group). All non-carriers will be assigned to the placebo group. CDR-GS at the end of Part 1 and the amyloid level using the last completed amyloid PET scan in Part 1 will be used for stratification. All study participants will participate in a double-dummy design for the duration of Part 2 receiving both an intravenous (IV) infusion at the required interval for the donanemab or matching placebo as well as a daily oral treatment of RG6289 or matching placebo.
An exploratory outcome of Part 1 is a comparison of the amyloid clearance between this ADAD cohort and historical controls using propensity score matching. The primary outcome in Part 2 is change from the start of Part 2 through the end of Part 2 in brain amyloid load in PSEN1 E280A mutation carriers as measured by amyloid PET imaging. Other endpoints will include fluid and imaging biomarkers and measures of cognition and functioning. The maximum study duration for any individual participant will be 3 years, not including the screening or follow-up periods

Start Date15 Jan 2026

Sponsor / Collaborator

Banner Health

[+2]

NCT06566170

/ RecruitingNot Applicable

Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

Start Date07 Oct 2024

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Donanemab-AZBT

100 Translational Medicine associated with Donanemab-AZBT

100 Patents (Medical) associated with Donanemab-AZBT

296

Literatures (Medical) associated with Donanemab-AZBT

01 Mar 2026·MOLECULAR AND CELLULAR NEUROSCIENCE

Precision therapeutic strategies for Alzheimer's disease: Amyloid β–targeted foundations and multimodal next-generation approaches

Review

Author: Shafiq, Shaista ; Khan, Muhammad Sohail ; Zafar, Imran ; Khan, Najeeb Ullah ; Jamal, Adil ; Bahwerth, Fayez Saeed

Alzheimer's disease (AD) is the leading cause of dementia and a significant unmet medical challenge, pathologically characterized by amyloid β (Aβ) aggregation, tau hyperphosphorylation, synaptic dysfunction, and chronic neuroinflammation. Although Aβ has long been a central therapeutic target, clinical translation has historically been hindered by late-stage intervention, inadequate blood-brain barrier (BBB) penetration, and the molecular heterogeneity of AD. Recent advances with Aβ-targeted monoclonal antibodies, particularly lecanemab and donanemab, have provided the first clinical evidence of disease modification, demonstrating robust amyloid clearance and measurable slowing of cognitive decline in early-stage AD. These results validate the Aβ hypothesis but also highlight persistent barriers, including amyloid-related imaging abnormalities (ARIA), questions about the durability of benefit, challenges in patient stratification, and the high economic burden of biologics. To overcome these limitations, next-generation strategies are emerging that extend beyond single-pathway targeting toward multimodal and precision-based frameworks. Innovative approaches include tau-directed therapies to prevent the propagation of neurofibrillary tangles, immunomodulatory strategies to enhance microglial clearance of aggregated proteins, and neuroprotective interventions to counteract oxidative and inflammatory stress. Concurrently, nanotechnology-based drug delivery systems are being engineered to efficiently traverse the BBB and deliver multifunctional payloads, while artificial intelligence (AI)- driven discovery platforms are accelerating target identification, biomarker integration, and patient stratification. Future perspectives emphasize the importance of preclinical-stage intervention, long-term efficacy trials, and the adoption of personalised treatment paradigms that integrate genomic, biomarker, and digital profiling to optimise outcomes. Collectively, these advances signal a paradigm shift in AD therapeutics, positioning Aβ-targeted therapies as a foundation while paving the way for combination strategies that more effectively address the disease's multifactorial nature.

01 Mar 2026·JPAD-Journal of Prevention of Alzheimers Disease

A regional framework for the detection and management of ARIA with anti-amyloid therapies in early Alzheimer’s disease in Asia

Article

Author: Inaba, Kaori ; Chen, Ta-Fu ; Moon, Won Jin ; Kandiah, Nagaendran ; Kumar, Sumeet ; Park, Young Ho ; Dash, Amitabh ; Lee, Bo-Ching ; Moon, So Young

Alzheimer's disease (AD) is a growing public health concern in Asia, with an increasing prevalence driven by demographic shifts and rising life expectancy. The introduction of anti-amyloid monoclonal antibodies such as lecanemab and donanemab marks a pivotal transition from symptomatic management of AD to disease-modifying approaches, but their clinical use requires careful monitoring for amyloid-related imaging abnormalities (ARIA), a key safety consideration that presents either as vasogenic edema or as microhemorrhages and superficial siderosis. ARIA has been observed in varying frequencies across global and Asian clinical trial populations, underscoring the need for region-specific guidance. With our early clinical experiences in South Korea, Taiwan and Singapore serving as archetypes in Asia, we outline a framework for the detection and management of ARIA in Asian healthcare settings, accounting for disparities in imaging infrastructure, genetic factors, and clinician experience. Pre-treatment risk stratification, standardized imaging protocols, and severity-based treatment modifications are central to the framework, highlighting the critical role of multidisciplinary collaboration involving neurologists, geriatricians, psychiatrists, and radiologists in ensuring accurate detection and management of ARIA. Additionally, the paper highlights the role of pharmacovigilance, real-world evidence generation, physician education, and healthcare system preparedness in optimizing the safety and efficacy of anti-amyloid therapies in Asia. The proposed framework aims to ensure safe and effective use of anti-amyloid therapies while mitigating ARIA-related risks, thereby optimizing therapeutic outcomes for early AD in diverse healthcare settings across Asia.

01 Mar 2026·JPAD-Journal of Prevention of Alzheimers Disease

Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic

Article

Author: Westman, Eric ; Daniilidou, Makrina ; Matton, Anna ; Hall, Anette ; Bonnard, Alexandre ; Solomon, Alina ; Rosenberg, Anna ; Hagman, Göran ; Kivipelto, Miia ; Öhlund-Wistbacka, Ulf

Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are excluded. Successful implementation in public healthcare hinges on accurate estimates of eligibility rates in settings which will be the first to roll out the treatments (specialized memory clinics with early disease stages). We applied the appropriate use recommendations (AUR) to assess treatment eligibility in a Swedish tertiary memory clinic where Aβ and APOE assessments are routinely performed. Of the full cohort (N = 410), 26 and 25 patients met the AUR criteria for lecanemab and donanemab, respectively (6 %; partial overlap between the groups). After excluding APOE ε4/4 carriers in line with the European guidelines, only 14 and 13 patients remained eligible (3 %). In clinics with younger populations, a significant percentage of potentially eligible patients are likely to have the APOE ε4/4 genotype. These findings are important to inform the implementation of anti-Aβ treatments.

610

News (Medical) associated with Donanemab-AZBT

20 Feb 2026

·www.fiercebiotech.com

Ionis scraps early candidate for Alzheimer\'s in people with Down syndrome

More than half of people with Down syndrome develop Alzheimer’s dementia as they age, with telltale bundles of amyloid and tau proteins forming in many of their brains by the age of 40.\n Ionis Pharmaceuticals has pulled the plug on an early investigational treatment for Alzheimer’s disease in people with Down syndrome, marking another setback for a group of patients who are both at higher risk for the neurodegenerative condition and not served by currently approved therapies.The California biopharma terminated a phase 1 trial of ION269 and has dropped the candidate from its pipeline, an Ionis spokesperson confirmed to Fierce Biotech.“This decision was made based on multiple factors, including slow enrollment, and is not related to concerns with the study drug,” the spokesperson said. After kicking things off in December 2024, Ionis has now shut down the trial with just one patient enrolled, according to the federal clinical trial database.With ION269 shelved, Ionis is instead focusing on other “high potential programs” in its neurology pipeline, the spokesperson added, including a phase 3 program for a rare genetic disease called Angelman syndrome. More than half of people with Down syndrome develop Alzheimer’s dementia as they age, with telltale bundles of amyloid and tau proteins forming in many of their brains by the age of 40, according to the National Institute on Aging.Despite this increased risk, neither Eli Lilly’s Kisunla (donanemab) nor Biogen and Eisai’s Leqembi (lecanemab) has been tested in people with Down syndrome. These antibodies, the only two disease-modifying medicines for the disease, target amyloid plaques in the brain. “Unfortunately, no one with Down syndrome was included in the clinical trials of Kisunla, nor in any of the previous trials in this drug class,” Hampus Hillerstrom, CEO of advocacy group LuMind IDSC, said in a statement when Kisunla was approved in July 2024. “So, we still don’t know if Kisunla or any other anti-amyloid drugs are safe for people with Down syndrome.”While Kisunla and Leqembi have demonstrated their ability to clear amyloid plaques, their ability to slow cognitive decline is typically modest, and both come with a risk of a dangerous brain bleeding side effect called amyloid-related imaging abnormalities, or ARIA. Studies have found that people with Down syndrome are at higher risk of suffering Alzheimer’s-related brain bleeds, and the appropriate use recommendations for both Kisunla and Leqembi advise not giving the meds to people with Down syndrome.Lilly has expressed a commitment to testing Kisunla in Alzheimer’s patients with Down syndrome. A trial testing donanemab in around 60 people with Down syndrome is set to kick off in August, according to the federal clinical trials database.A host of other anti-amyloid antibodies, specifically designed to reduce the risk of ARIA, are also in the works, including candidates from Roche, AbbVie, Denali Therapeutics and newcomer Korsana Biosciences. These antibodies, too, though, are not being developed with Down syndrome patients in mind.

Phase 3Drug Approval

18 Feb 2026

·endpoints.news

Paragon's latest biotech will try to slow Alzheimer's like Roche

Biologics maker Paragon Therapeutics has spun out its seventh biotech startup, this time in pursuit of Roche in the fight against Alzheimer’s. Like Roche with trontinemab, Korsana Biosciences is attempting to deliver an antibody that shuttles across the blood-brain barrier to thwart the advancement of the memory-robbing disease. Korsana disclosed its lead asset Wednesday along with the news that it raised a $150 million Series A in September to help get to early clinical data. Investors included Fairmount, Venrock Healthcare Capital Partners, Wellington Management, TCGX, JP Morgan Life Sciences Private Capital, Janus Henderson Investors and Foresite Capital. Sanofi’s venture arm, one of the most active biotech investors of late, also took part. The nine-figure Series A marks at least the 15th megaround that private biotech startups have disclosed so far this year. The Waltham, MA-based startup was seeded with $25 million in 2024. The biotech’s battle against Alzheimer’s is much further behind than Roche’s trontinemab program, which is seen as a leading shot in the next wave of Alzheimer’s treatments and entered a set of large Phase 3 trials last year. Trontinemab “is not the end of the road — we do not think it’s the best you can do for these patients,” Korsana CEO Jonathan Violin said in an interview with Endpoints News. Korsana anticipates entering Phase 1/2 with its candidate KRSA-028 around the end of this year or early next year. It expects Phase 1 healthy volunteer results in mid-2027 and then initial data on KRSA-028’s amyloid plaque-clearing capabilities around the end of that year. The nimble 17-employee startup is betting one of its advantages will be a delivery route that eliminates the need to go to infusion centers, Violin said. Korsana is cooking up a subcutaneously delivered medicine, whereas Roche is testing an IV-formulated antibody. Korsana also hopes to tamp down on concerning side effects that have affected the inaugural class of approved amyloid-targeted medicines, namely Eli Lilly’s Kisunla and Biogen and Eisai’s Leqembi. While those treatments ended a bleak “graveyard” period for Alzheimer’s drug development, they can carry the risk of concerning side effects known as amyloid-related imaging abnormalities, which can signal brain swelling and bleeding. ARIAs are a “challenge for anyone to contemplate,” Violin said. That’s one way that trontinemab has changed the game so far in clinical testing. “The data that Roche has released is compelling, not only to take less drug, but plaques are cleared much more quickly, much more robustly and the rate of ARIA is substantially diminished,” Violin said. Other companies want to join Roche in the brain-shuttle arena. AbbVie acquired Aliada for $1.4 billion in 2024. Novartis has launched a broad approach through pacts with SciNeuro , Sironax and BioArctic . The latter is also teaming with Bristol Myers Squibb and Eisai . Roche itself is doubling down on the blood-brain-barrier approach with Manifold Bio , among others. With the competitive pressure dialed up, Korsana is staying relatively quiet on development plans, including which stage of Alzheimer’s progression it intends to attack and what type of treatment course it’s eyeing. Leqembi is meant to be taken chronically, while Lilly’s Kisunla is supposed to be stopped after amyloid plaques sink to a certain level. The best data so far are in mild cognitive impairment, but some analyses suggest that “earlier intervention is better,” Violin said. “We’ll see some data readouts from companies like Lilly before we need to make decisions.” Kisunla is in a Phase 3 trial of patients with preclinical Alzheimer’s. Korsana’s existing funds will get the startup past its early clinical data readouts, Violin said. The company’s runway goes into 2028. With the padded reserves, Korsana can remain “opportunistic” on its next financing steps, Violin said. Other Paragon spinouts made quick leaps onto public markets. Spyre Therapeutics , Oruka Therapeutics and Crescent Biopharma all announced reverse mergers at the time of their unveilings. (Violin was CEO of Crescent when it decided to jump onto the Nasdaq.) Another Paragon offshoot, Jade Biosciences , went the reverse merger route just a few months after disclosing its launch. Apogee Therapeutics took a traditional IPO path. All of those companies have done private placements or additional financings since going public.

AcquisitionIPOPhase 3Phase 1

18 Feb 2026

·firstwordpharma.com

Korsana steps into Alzheimer's arena with antibody shuttle platform

Korsana Biosciences emerged from stealth Wednesday with $175 million in funding to develop treatments for neurodegenerative disease, including one for Alzheimer's designed to address drawbacks seen with currently marketed anti-amyloid drugs.Discovered in partnership with Paragon Therapeutics, its lead candidate, KRSA-028, is a mAb that targets amyloid-beta. The therapy incorporates Korsana's Therapeutic Targeting (THETA) brain-penetrant shuttle technology; by targeting transferrin receptor 1 (TfR1), THETA acts as a biological transport system that can ferry therapeutic antibodies across the blood-brain barrier.Several pharmas, including Novartis and Roche, have incorporated brain shuttle technologies into their Alzheimer's disease strategies. According to Korsana, the approach aims to increase drug concentrations inside the central nervous system (CNS) while bypassing perivascular spaces around the choroid plexus, which in turn could lower the risk of amyloid-related imaging abnormalities (ARIA), complications of brain swelling and microhaemorrhages that have been tied to Eli Lilly's Kisunla (donanemab) and Eisai and Biogen's Leqembi (lecanemab).Last year, Lilly won approval for a new dosing schedule aimed at reducing ARIA risk, an advance that appealed to neurologists who were polled by FirstWord, with seven in 10 respondents saying they were somewhat or more likely to prescribe Kisunla as a result (see – Physician Views Results: Kisunla widens its lead over Leqembi with new, safer dosing).Meanwhile, Korsana said its compound also includes Fc engineering to preserve plaque-clearing activity while reducing immune-mediated toxicity and extending half-life, potentially allowing for the drug to be administered via low-volume subcutaneous route."Only two disease-modifying therapies have been approved to treat Alzheimer's, and both carry safety warnings, offer only modest efficacy, and impose a high burden of care," CEO Jonathan Violin said in a release. "Patients deserve better options…and we believe our lead programme KRSA-028 can deliver a best-in-class product."Founded in 2024, Korsana is the seventh company built around assets developed by Paragon. The startup raised $25 million in seed financing from Fairmount and Venrock Healthcare Capital Partners before completing a $150-million private series A last September co-led by Wellington Management and TCGX, with participation by Sanofi Ventures, J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Foresite Capital, and others.The funding is expected to support development through early clinical milestones, including pharmacokinetic, CNS penetration and safety data in healthy volunteers targeted for mid-2027, followed by proof-of-concept data by the end of next year on whether it can clear amyloid plaques in Alzheimer's patients. The company expects its current capital to fund operations into 2028.

100 Deals associated with Donanemab-AZBT

External Link

KEGG	Wiki	ATC	Drug Bank
D11500	Donanemab-AZBT	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Alzheimer Disease	United States	Eli Lilly & Co.	02 Jul 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psychotic Disorders	NDA/BLA	Canada	Eli Lilly Canada, Inc.	-
Neurocognitive Disorders	Phase 3	China	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Argentina	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Australia	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Poland	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	South Korea	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Spain	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Taiwan Province	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	United Kingdom	Eli Lilly & Co.	10 Oct 2022
Cognitive Dysfunction	Phase 2	United States	Eli Lilly & Co.	23 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05738486 (TRAILBLAZER-ALZ 6, CTgov)	Phase 3	Alzheimer Disease \| Neurocognitive Disorders	1,175	Placebo+Donanemab (1400 mg Donanemab - Standard Regimen)	kcaxxzbhwc = abcijfkpnf udpxbxkwhl (oltmboeeef, goodeecjpm - grxdhtyugt) View more	-	14 Nov 2025
				Placebo+Donanemab (1400 mg Donanemab - Dose Skipping)	kcaxxzbhwc = mocwcgpqbq udpxbxkwhl (oltmboeeef, drgkmylulg - iwnuenvofg) View more
NCT05026866 (TRAILBLAZER-ALZ 3, Pubmed \| Alzheimers Dement)	Phase 1	Alzheimer Disease	2,196	Donanemab (CDR‐GS: 0)	krpwaozmek(tcqcvzopgf) = ipgjklqinh zbfrcbedcg (aimkwfzrat ) View more	Positive	01 Sep 2025
				Donanemab (CDR‐GS: 0.5)	neuogoksbk(nnxxvafkbi) = lzpjwkmafc iznxqxqwld (qoydxkcpxa ) View more
NCT04437511 (TRAILBLAZER-ALZ 2, PRNewswire) Manual	Phase 3	Alzheimer Disease	-	Kisunla	pnrzxmerpf(ktvktqkwmx): Difference = -0.6 View more	Positive	30 Jul 2025
				Neuroimaging Initiative (untreated external cohort)
NCT05108922 (TRAILBLAZER-ALZ 4, Pubmed \| Alzheimers Dement)	Phase 3	Alzheimer Disease amyloid plaque clearance	148	Donanemab	xhweddxgzm(hdyvyceenn) = nykbsxuygj gakkxfvydl (zfdjswfioc ) View more	Positive	01 May 2025
				Aducanumab	xhweddxgzm(hdyvyceenn) = vtcriliuap gakkxfvydl (zfdjswfioc ) View more
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ and ALZ 2, Pubmed \| JAMA Neurol)	Not Applicable	Alzheimer Disease APOE ε4 allele number \| amyloid levels	3,030	Donanemab	elpjoirsya(hqlmavakto) = dwkyasvidq vrpsnbonnu (nropnnfytc ) View more	Positive	01 May 2025
				Placebo	elpjoirsya(hqlmavakto) = nknsiwhwho vrpsnbonnu (nropnnfytc ) View more
NCT05738486 (TRAILBLAZER-ALZ 6, Company_Website 1 \| Company_Website 2) Manual	Phase 3	Alzheimer Disease	843	received two vials (700 mg) of donanemab for the first three infusions, then four vials (1400 mg) thereafterdonanemab for the first three infusions, then four vials (1400 mg) thereafter (Standard Dosing Regimen)	ugpubvjlwl(fygqnalyxh) = uernpppeqg avpmjqslff (gfqrrkvebi ) View more	Positive	29 Oct 2024
				received 1 vial (350 mg) of donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion,donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion, and four vials (1400 mg) per infusion thereafter (Modified Titration)	ugpubvjlwl(fygqnalyxh) = fjwfkopqrm avpmjqslff (gfqrrkvebi ) View more
NCT04437511 (TRAILBLAZER-ALZ 2, CTAD2024)	Phase 3	Alzheimer Disease amyloid \| tau	824	Donanemab	wupxhbqbai(vewgquqyyn) = awvakjbjzk tcxvpdoynq (sysfxsaoyc ) View more	Positive	29 Oct 2024
				Placebo	wupxhbqbai(vewgquqyyn) = bdgtdjlrrf tcxvpdoynq (sysfxsaoyc ) View more
NCT05026866 (TRAILBLAZER-ALZ 3, CTAD2024)	Phase 3	Alzheimer Disease P-tau217	2,196	Donanemab	aywwziljkq(gafzufkutc) = wneogtjaoq wnwurmhipa (dhhlicnibq, 0 - 0.84) View more	Positive	29 Oct 2024
				Placebo	aywwziljkq(gafzufkutc) = zjprfraqaq wnwurmhipa (dhhlicnibq, 0 - 1.34) View more
NCT05567159 (CTgov)	Phase 1	-	42	Donanemab	apvdzouyut(jpupsomcjv) = fgigzyuddw sokxywlwsc (vdbnkysvlf, 23) View more	-	04 Oct 2024
NCT01837641 (CTgov)	Phase 1	Alzheimer Disease \| Cognitive Dysfunction \| Mild cognitive disorder	63	Placebo (Placebo IV)	irfjxqlwvq = azzyoaocom xxiisfngse (bopcwlswgh, myerdziztw - duvbltmian) View more	-	04 Oct 2024
				LY3002813 (0.1 mg/kg / 0.3 mg/kg LY3002813 IV)	irfjxqlwvq = dvfjzuiyle xxiisfngse (bopcwlswgh, kxjsikinym - lbvyivaeck) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis